Beactica Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $294K

  • Investors
  • 11

Beactica Therapeutics General Information

Description

Developer of a drug discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The company's platform offers protein-based therapeutics that regulate the expression of disease-associated proteins in order to change the chromatin configuration that governs the regulation of DNA transcription and improve the immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lower risks.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Virdings allé 2
  • 754 50 Uppsala
  • Sweden
+46 018-56 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beactica Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 18-Jun-2019 $294K Completed Pre-Clinical Trials
7. Later Stage VC 04-Jun-2019 Completed Pre-Clinical Trials
6. Grant 23-Mar-2018 000.00 Completed Pre-Clinical Trials
5. Later Stage VC 15-Dec-2014 Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Pre-Clinical Trials
3. Grant 20-Nov-2014 00000 Completed Pre-Clinical Trials
2. Grant 14-Sep-2007 $187K Completed Pre-Clinical Trials
1. Early Stage VC 22-Nov-2006 Completed Startup
To view Beactica Therapeutics’s complete valuation and funding history, request access »

Beactica Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The compa
Drug Discovery
Uppsala, Sweden
17 As of 2023
0000000000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000 000000000
Cambridge, MA
00 As of 0000
0000
00000 0000-00-00
000000&0 0000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
Basel, Switzerland
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beactica Therapeutics Competitors (102)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mitobridge Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
Cellestia Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
Theolytics Venture Capital-Backed Oxford, United Kingdom 00 000.00 0000000000 0 000.00
NeoPhore Venture Capital-Backed Cheshire, United Kingdom 00 000.00 00000000000 000.00
Plexium Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
You’re viewing 5 of 102 competitors. Get the full list »

Beactica Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Per Kallblad Ph.D Co-Founder, Chief Executive Officer & Board Member
Hakan Wickholm President & Chairman
Helena Danielson Ph.D Co-Founder, Scientific Advisor & Board Member
Jan-Olof Karlsson Head of Finances
You’re viewing 4 of 7 executive team members. Get the full list »

Beactica Therapeutics Board Members (14)

Name Representing Role Since
Christina Herder Ph.D Self Board Member 000 0000
Erik Walldén Self Board Member 000 0000
Hakan Wickholm Beactica Therapeutics President & Chairman 000 0000
Helena Danielson Ph.D Beactica Therapeutics Co-Founder, Scientific Advisor & Board Member 000 0000
Jarl Jungnelius Ph.D Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Beactica Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beactica Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SWElife Government 000 0000 000000 0
Flerie Venture Capital Minority 000 0000 000000 0
M2Capital PE/Buyout Minority 000 0000 000000 0
Paab Venture Capital Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Beactica Therapeutics FAQs

  • When was Beactica Therapeutics founded?

    Beactica Therapeutics was founded in 2006.

  • Who is the founder of Beactica Therapeutics?

    Per Kallblad Ph.D and Helena Danielson Ph.D are the founders of Beactica Therapeutics.

  • Who is the CEO of Beactica Therapeutics?

    Per Kallblad Ph.D is the CEO of Beactica Therapeutics.

  • Where is Beactica Therapeutics headquartered?

    Beactica Therapeutics is headquartered in Uppsala, Sweden.

  • What is the size of Beactica Therapeutics?

    Beactica Therapeutics has 17 total employees.

  • What industry is Beactica Therapeutics in?

    Beactica Therapeutics’s primary industry is Drug Discovery.

  • Is Beactica Therapeutics a private or public company?

    Beactica Therapeutics is a Private company.

  • What is Beactica Therapeutics’s current revenue?

    The current revenue for Beactica Therapeutics is 000000.

  • Who are Beactica Therapeutics’s investors?

    SWElife, Flerie, M2Capital, Paab, and Horizon 2020 SME Instrument are 5 of 11 investors who have invested in Beactica Therapeutics.

  • Who are Beactica Therapeutics’s competitors?

    Mitobridge, Cellestia, Theolytics, NeoPhore, and Plexium are some of the 102 competitors of Beactica Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »